IP Library Granted Patent US 10,612,076
Granted Patent B2
US 10,612,076 · App. 15/483,282 · Granted Apr 7, 2020

Selective oxidation of 5-methylcytosine by TET-family proteins

Inventors: Anjana Rao (La Jolla, CA); Mamta Tahiliani (New York, NY); Kian Peng Koh (Jamaica Plain, MA); Suneet Agarwal (Belmont, MA); Aravind Iyer (Bethesda, MD)
Assignees: The Children's Medical Center Corporation; The U.S.A., As Represented by the Secretary, Department of Health & Human Services
C12Q1/6827C12N5/0018C12N5/0607C12N5/0637C12N5/0696C12N9/0071C12N15/873C12Q1/26C12Q1/6806C12Q1/6869C12Q1/6886G01N33/5011G01N33/5308G01N33/57426G01N33/57484G01N33/57496C12N2501/15C12N2501/602C12N2501/603C12N2501/604C12N2501/606C12N2501/70C12N2501/71C12N2501/999C12N2506/1307C12N2506/1353C12N2510/00C12Q2521/531C12Q2522/10C12Q2537/164C12Q2600/154G01N2500/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,612,076
App. No.
15/483,282
Granted
Apr 7, 2020
Kind
B2
Abstract

The present invention provides for novel methods for regulating and detecting the cytosine methylation status of DNA. The invention is based upon identification of a novel and surprising catalytic activity for the family of TET proteins, namely TET1, TET2, TET3, and CXXC4. The novel activity is related to the enzymes being capable of converting the cytosine nucleotide 5-methylcytosine into 5-hydroxymethylcytosine by hydroxylation.

Claims (25)

1. A method comprising:

regulating a methylation status of one or more cytosine bases in an adult cell that is isolated and purified, wherein the regulating comprises contacting the adult cell with an effective amount of:

(i) an enzyme or fragment thereof that converts:

(a) 5-methylcytosine to 5-hydroxymethylcytosine,

(b) 5-methylcytosine to an acid beyond hydroxymethlyation, or

(c) 5-methylcytosine to an aldehyde beyond hydroxymethlyation;

(ii) an inhibitor that decreases or prevents hydroxymethylation, wherein the inhibitor comprises siRNA or shRNA; or

(iii) a combination thereof, and

wherein the methylation status of the one or more cytosine bases in the adult cell is regulated.

2. The method of claim 1 , wherein the adult cell is a naive T cell.

3. The method of claim 1 , wherein the adult cell is a peripheral T cell.

4. The method of claim 1 , wherein the adult cell is a purified human CD4+ T cell.

5. The method of claim 2 , wherein the regulating differentiates the naive T cell to a regulatory T cell, and wherein the regulatory T cell is a Foxp3+ T cell.

6. The method of claim 1 , wherein the one or more cytosine bases are positioned in a CpG site, a CpG island, or a combination thereof in the adult cell.

7. The method of claim 1 , further comprising contacting the adult cell with a cytokine, a growth factor, or an activating reagent.

8. The method of claim 7 , wherein the adult cell is contacted with the cytokine, and wherein the cytokine comprises TGF-beta.

9. The method of claim 7 , wherein the adult cell is contacted with the activating agent, and wherein the activating reagent comprises retinoic acid.

10. The method of claim 2 , wherein the naive T cell comprises a plurality of naive T cells, and wherein a percentage of regulatory T cells generated from the regulating of (a) is at least 5% higher in the plurality of naive T cells than a control population of naive T cells generated without the effective amount of (a).

11. The method of claim 2 , wherein the regulating differentiates the naive T cell to a regulatory T cell, and wherein the regulatory T cell maintains a characteristic function in the absence of an exogenous differentiation factor.

12. The method of claim 11 , wherein the characteristic function comprises a suppression of proliferation of naive T cells.

13. The method of claim 1 , wherein the method comprises contacting the adult cell with an effective amount of the enzyme or fragment thereof in (i) that is a recombinant enzyme or a fragment of a recombinant enzyme.

14. The method of claim 1 , wherein the method comprises contacting the adult cell with an effective amount of the enzyme or fragment thereof in (i) that comprises a mutation in a sequence corresponding to the enzyme or fragment thereof.

15. The method of claim 1 , wherein the method comprises contacting the adult cell with an effective amount of the enzyme or fragment thereof in (i) that comprises at least a portion of a TET family enzyme or a fragment thereof.

16. The method of claim 1 , wherein the method comprises contacting the adult cell with an effective amount of the enzyme or fragment thereof in (i) that is TETI, TET2, TET3, CXXC4, a fragment of any of these, or any combination thereof.

17. The method of claim 1 , wherein the method comprises contacting the adult cell with an effective amount of the enzyme or fragment thereof in (i) that comprises a nucleic acid sequence having at least about 90% sequence homology to any one of: SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, or SEQ ID NO: 5.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 14, 2017
From: IYER, ARAVIND
To: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Reel/Frame 043585/0255 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 6, 2017
From: RAO, ANJANA; TAHILIANI, MAMTA; KOH, KIAN PENG
To: IMMUNE DISEASE INSTITUTE, INC.
Reel/Frame 043506/0504 →
MERGER Recorded Sep 6, 2017
From: IMMUNE DISEASE INSTITUTE, INC.
To: THE CHILDREN'S HOSPITAL CORPORATION
Reel/Frame 043506/0508 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 6, 2017
From: THE CHILDREN'S HOSPITAL CORPORATION
To: CHILDREN'S MEDICAL CENTER CORPORATION
Reel/Frame 043506/0535 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 6, 2017
From: AGARWAL, SUNEET
To: CHILDREN'S MEDICAL CENTER CORPORATION
Reel/Frame 043506/0539 →
Continuity (8)
Continuation 15341344 · Nov 2, 2016
Continuation 15193796 · Jun 27, 2016
Continuation 13795739 · Mar 12, 2013
Continuation 13120861
Provisional Application 61100503 · Sep 26, 2008
Provisional Application 61100995 · Sep 29, 2008
Provisional Application 61121844 · Dec 11, 2008
Related Publication 20170218338A1 · Aug 3, 2017
Cited By (5)
US 12,291,742 US 12,331,346 US 12,338,489 US 12,467,082 US 12,630,866